SOLV — Solventum Corporation

Tone turned constructive after the 2026-08-05 Q2 2026 report: $2.21B revenue, +9.5% organic (versus +2.2% reported), adjusted diluted EPS of $2.55 (+50.9% YoY), a raised FY2026 organic-sales/adjusted-EPS/free-cash-flow guide, and the announced HIS spinoff. Price action confirms it as of 2026-09-13 — +10.88% over three months and +30.99% over six months — even though the most recent week gave back 4.62%. Sell-side is constructive but not euphoric: FMP shows 9 Buy / 2 Hold / 1 Sell with a $91.22 consensus target and a $97.25 recent-average target, and the residual caution is concentrated on the $4.57B of long-term debt and the wide GAAP-to-adjusted earnings gap.

Revenue was dead flat at roughly $2.0–2.1B for twelve straight quarters (Q3 2023 through Q1 2026) and then inflected — Q2 2026 printed $2,209M, the highest in the dataset, up 2.2% reported but 9.5% organic, with the ~7-point gap being FX/divestiture drag that is now the single biggest swing factor in reported growth. The GAAP operating margin is a spinoff-financing story, not a demand story: it fell from 18.9% in Q1 2024 to a trough of 4.0% in Q1 2026 as standalone public-company, IT-separation and restructuring costs landed, then rebounded to 8.2% in Q2 2026, while gross margin held a healthy 54–58% band (58.2% in Q2 2026). The most concrete improvement is on the balance sheet: long-term debt fell from $8.31B (Q2 2024) to $4.57B (Q2 2026) and stockholders' equity rose from $2.87B to $4.80B. Two important caveats: the GAAP earnings trend is polluted by a one-time gain in Q3 2025 ($7.22 EPS and $1,266M net income on just $137M operating income) and an anomalous $1,678M operating-income line in Q4 2025; and free cash flow is deteriorating, with TTM FCF of roughly -$118M after a $805M FCF year in 2024.

The headline 10.6x TTM P/E is a trap — TTM EPS of $8.265 contains the one-time Q3 2025 gain and is not a real earnings multiple. On next-FY consensus EPS of $7.16, SOLV traded at ~12.2x as of 2026-09-13, essentially in line with its own five-year average P/E of 12.54x and cheap versus MedTech peers that generally trade in the high teens. Price/sales is the dissenting metric: 1.82x versus a 1.62x five-year average, a ~12% premium to its own history, and price/cash flow of 37.8x and P/B of 3.16x are both artifacts of the carve-out equity reset. EV/EBITDA is roughly 7.8–8x on trailing figures. Net verdict: fairly valued to modestly cheap on earnings and EBITDA, mildly rich on sales and book — a fair description of a leveraged, slow-growth carve-out that is only just beginning to inflect.

The market is paying ~12x forward adjusted EPS of $7.16 — a multiple that prices in 'steady, unspectacular' and gives almost no credit for 9.5% organic growth, the quarter-over-quarter margin recovery, or the HIS separation. That is the asymmetry: if the raised FY2026 guide is hit and the spinoff executes on a tax-free basis toward the high-end targets of $113–118, the multiple has room to re-rate into the mid-teens. The flip side is that the multiple is only defensible if the GAAP-to-adjusted bridge shrinks — Q2 2026 showed $2.55 adjusted EPS against $0.53 GAAP, and until that gap narrows the market will keep discounting the adjusted number. The single most important next datapoint will be the Q3 2026 free-cash-flow trajectory (expected late October/early November 2026), because TTM FCF is negative and the raised FCF guide is the one number that must be proven rather than promised.

As of 2026-09-13 the stock sat at $87.45 with RSI at 46.29 — neutral, neither oversold nor overbought. It was 2.76% below its 20-day SMA but 3.06% above its 50-day and 12.72% above its 200-day, the classic footprint of an uptrend taking a breather rather than a trend break. Medium-term momentum is clearly positive (+10.88% three-month, +30.99% six-month) but short-term is negative (-4.62% one week), and the stock is ~7% off its 52-week high of $94.16. Practical read: no urgency and no alarm. A pullback into the 50-day area would be a better entry than chasing into the 52-week high, and a break below the 200-day would be the signal that the margin-and-spinoff story is being repriced lower.

• Rate sensitivity: $4.57B of long-term debt as of 2026-06-30 means every refinancing and every 25bp of policy-rate movement flows straight into interest expense and the equity story — falling rates are a direct tailwind, sticky rates keep the multiple compressed.
• Input-cost inflation and tariffs: management continues to flag raw-material price pressure and trade-policy/tariff risk on components, partly offset by pricing power and internal cost-reduction programs.
• FX translation: reported growth of +2.2% versus organic +9.5% in Q2 2026 shows a large currency/divestiture drag — a weaker dollar is a meaningful and underappreciated earnings lever.
• Secular MedTech demand: aging demographics, procedure-volume recovery, preventive dental care, and hospital workflow spend provide a steady low-single-digit-plus volume baseline.
• Healthcare policy and reimbursement: hospital capex cycles, reimbursement changes, and any medtech-specific regulatory or tax shifts remain sector-level swing factors outside management's control.

• Health Information Systems separation (announced 2026-08-05): the structural timeline, tax-free mechanics, and eventual standalone valuation are the single biggest value-unlock lever.
• Q3 2026 results (expected late October/early November 2026): the first real test of the raised FY2026 organic-growth, adjusted-EPS, and free-cash-flow guidance — free cash flow matters most given negative TTM FCF.
• Fall investor conferences (e.g. Wells Fargo Healthcare in September 2026): management color on long-term margin expansion and the taper of separation-related friction costs heading into 2027.
• Continued deleveraging: another leg down in long-term debt or a credit-rating upgrade would de-risk the balance sheet and likely re-rate the multiple.
• Post-separation ownership effects: reclassification into a cleaner MedTech pure-play could shift the shareholder base and change the peer multiple the market applies.

• Balance sheet tightness: $4.57B long-term debt, debt/equity of 1.10, current ratio of 1.02 and quick ratio of 0.74 leave essentially no liquidity cushion and make the equity highly sensitive to rates and any earnings miss.
• Cash conversion: TTM free cash flow was roughly -$118M as of 2026-06-30, including a -$273M Q1 2026 outflow; 2025 FCF was about -$10M versus +$805M in 2024, and a raised FCF guide does not erase that track record.
• Earnings quality: $2.55 adjusted EPS versus $0.53 GAAP in Q2 2026, plus the one-time Q3 2025 gain that inflates TTM EPS to $8.265, means headline multiples understate the true earnings yield.
• Spinoff execution: separating HIS carries dis-synergies, stranded costs, and management distraction, with no guarantee the market rewards a smaller, more levered remaining MedTech.
• Input costs and FX: reported growth has repeatedly lagged organic growth by a wide margin, and raw-material inflation is only partly offset by pricing.
• Competitive scale: as a standalone carve-out, Solventum lacks the scale and balance-sheet flexibility of the large diversified MedTech peers it competes against.

Solventum is a decent, genuinely improving MedTech with a real catalyst — but after a 31% six-month run the easy money has been made. Q2 2026's 9.5% organic growth, the sequential margin rebound, the ~$3.7B of long-term debt retired since mid-2024, and the announced HIS separation are all real positives that a 12x forward P/E does not fully reflect. Against that, TTM free cash flow is negative, the current and quick ratios are thin, and the GAAP-to-adjusted earnings gap is wide enough that headline multiples flatter the business. My calculated fair value is about $92 versus $87.45 on 2026-09-13 — mid-single-digit upside, with leverage and cash-flow execution risk doing most of the offsetting. Not a mistake to own, but not a bargain worth chasing at this level.

I anchored on a forward P/E and cross-checked with EV/EBITDA: 13.0x the $7.16 next-FY consensus EPS gives $93.08 — a ~4% premium to the 12.54x five-year average P/E, justified by the jump to +9.5% organic growth, the Q1-to-Q2 2026 GAAP operating-margin rebound, ~$3.7B of long-term debt retired since Q2 2024, and the announced HIS separation — while ~9.0x EV/EBITDA on roughly $2.2B of forward EBITDA, less ~$4.2B of net debt and divided by 173.2M shares, gives about $90.25. The $91.67 midpoint rounds to $92.